Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 4;79(3):614–628. doi: 10.1161/HYPERTENSIONAHA.121.18415

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors.

Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.

PMC Copyright notice

Figure 2. — Estimated sample size per arm from trial sequential analysis, for future drug-vs-drug to reach 5% statistical significance with 90% power for various risk reductions in severe hypertension. The comparisons are β-blocker vs calcium channel blocker (red), methyldopa vs β-blocker (green), methyldopa vs calcium channel blocker (blue) and methyldopa vs labetalol (purple). The vertical dotted line represents a median severe hypertension rate of 13%.